The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus

Fanny Georgi, Vardan Andriasyan, Robert Witte, Luca Murer, Silvio Hemmi, Lisa Yu, Melanie Grove, Nicole Meili, Fabien Kuttler, Artur Yakimovich, Gerardo Turcatti, Urs F. GreberAntimicrobial 2020 · DOI

TL;DR

This study reveals that nelfinavir, an FDA-approved HIV drug, can inhibit the lytic, cell-free spread of human adenoviruses (HAdVs). Interestingly, it also uncovers a previously underappreciated nonlytic, cell-to-cell transmission route for HAdVs, suggesting nelfinavir has repurposing potential for treating adenovirus infections.

What Problem Does This Paper Address?

Human adenoviruses (HAdVs) are common pathogens causing a range of illnesses, from respiratory disease to more severe conditions in immunocompromised individuals. While some HAdVs are known for their ability to lyse cells (a process enhanced by the adenovirus death protein, ADP), there's a lack of specific FDA-approved antiviral treatments for HAdV infections. This paper addresses this gap by investigating the potential of repurposing existing drugs, specifically nelfinavir, an HIV protease inhibitor, as an anti-HAdV agent. The authors aim to understand how nelfinavir affects HAdV infection and transmission, particularly focusing on the mechanisms of cell lysis and viral spread.

Methods

The researchers employed a multi-pronged approach:

  • High-Throughput Image-Based Screening: This was used to identify potential inhibitors of HAdV-C2 infection.
  • Fluorescence Microscopy: This was crucial for visualizing infection foci, viral particles, and cellular changes. They used GFP-tagged HAdV-C2 to track infection.
  • Cell Viability and Toxicity Assays (XCELLigence): These assays measured the impact of nelfinavir on uninfected cells to determine its toxicity and therapeutic index.
  • Plaque Assays: Standard plaque assays were used to quantify viral spread and the effect of nelfinavir on plaque formation. They also analyzed plaque morphology (comet-shaped vs. round).
  • Transmission Electron Microscopy (TEM): Used to visualize viral particles within infected cells.
  • Western Blotting: Employed to assess viral protein maturation, specifically the processing of capsid proteins.
  • SDS-PAGE: Used in conjunction with Western blotting to analyze protein integrity.
  • Viral DNA Replication Assays: While not explicitly detailed as a primary method for nelfinavir's mechanism, the paper mentions assessing viral genome replication indirectly.
  • Generation of ADP-Deleted HAdV Mutants: This was a key genetic approach to dissect the role of ADP in nelfinavir's efficacy.
  • Immunofluorescence Staining: Used to detect viral proteins (like hexon and ADP) and cellular structures.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell culture experiments using various HAdV strains and human cell lines.

Key Insights and Ideas

  • Nelfinavir as a Lytic Transmission Inhibitor: The most striking finding is that nelfinavir effectively blocks the lytic, cell-free spread of HAdVs. This is visualized by the suppression of "comet-shaped" infection foci, which are characteristic of this transmission mode.
  • Uncovering Nonlytic Transmission: Perhaps even more surprising, nelfinavir treatment revealed a distinct, slow-growing, round plaque phenotype. This suggests that HAdVs can also spread via a nonlytic, cell-to-cell mechanism that is usually masked by the more rapid lytic spread.
  • ADP's Role in Nelfinavir Sensitivity: The study highlights that the presence of the adenovirus death protein (ADP) is crucial for nelfinavir's potent inhibitory effect on lytic spread. HAdVs lacking ADP are significantly less sensitive to nelfinavir.
  • Repurposing Potential: The paper strongly advocates for the repurposing of nelfinavir, an FDA-approved HIV drug, as a potential antiviral for HAdV infections, demonstrating postexposure efficacy.
  • Differential Susceptibility Across HAdV Types: Nelfinavir's efficacy varies across different HAdV species and types, with HAdV-C and -B14 showing higher sensitivity.

Key Results

  • Nelfinavir is a potent, non-toxic inhibitor of HAdV-C multicycle infection, with an EC50 of 0.37 µM and a therapeutic index (TI50) of 27.1 in A549 cells.
  • Nelfinavir does not affect single-round infection, meaning it doesn't inhibit viral entry, assembly, or maturation. Instead, it specifically targets viral egress.
  • Nelfinavir significantly inhibits the release of infectious progeny virions into the supernatant, reducing viral yield by up to 3 orders of magnitude.
  • ADP-deleted HAdV-C2 mutants are much less sensitive to nelfinavir, requiring significantly higher concentrations for inhibition.
  • Nonlytic, round plaques were observed in nelfinavir-treated cells and in unperturbed infections with limiting virus input, suggesting a dual transmission strategy for HAdVs.
  • Nelfinavir exhibits a broad anti-HAdV spectrum, with varying degrees of efficacy against different HAdV species (A, B, C, and D).

Limitations and Future Work

  • Mechanism of Nonlytic Transmission: While the study identifies a nonlytic transmission mode, the precise molecular mechanisms underlying this pathway remain to be fully elucidated. The authors speculate about WASH complex or ESCRT involvement.
  • ADP Localization and Nelfinavir Interaction: The study suggests nelfinavir might interfere with ADP's palmitoylation in the Golgi, which could be crucial for its lytic function. Further investigation into this interaction is warranted.
  • In Vivo Efficacy: The study is primarily conducted in cell culture. Future work should focus on evaluating nelfinavir's efficacy and safety in animal models and ultimately in human clinical trials for HAdV infections.
  • Differential Susceptibility: Understanding why certain HAdV types are more or less susceptible to nelfinavir could lead to more targeted therapeutic strategies.
  • Clinical Relevance of Nonlytic Transmission: The significance of the nonlytic transmission pathway in human disease, particularly in persistent infections, needs further exploration.

Summary updated

Abstract

Adenoviruses (AdVs) are prevalent and give rise to chronic and recurrent disease. Human AdV (HAdV) species B and C, such as HAdV-C2, -C5, and -B14, cause respiratory disease and constitute a health threat for immunocompromised individuals. HAdV-Cs are well known for lysing cells owing to the E3 CR1-β-encoded adenovirus death protein (ADP). We previously reported a high-throughput image-based screening framework and identified an inhibitor of HAdV-C2 multiround infection, nelfinavir mesylate. Nelfinavir is the active ingredient of Viracept, an FDA-approved inhibitor of human immunodeficiency virus (HIV) aspartyl protease that is used to treat AIDS. It is not effective against single-round HAdV infections. Here, we show that nelfinavir inhibits lytic cell-free transmission of HAdV, indicated by the suppression of comet-shaped infection foci in cell culture. Comet-shaped foci occur upon convection-based transmission of cell-free viral particles from an infected cell to neighboring uninfected cells. HAdV lacking ADP was insensitive to nelfinavir but gave rise to comet-shaped foci, indicating that ADP enhances but is not required for cell lysis. This was supported by the notion that HAdV-B14 and -B14p1 lacking ADP were highly sensitive to nelfinavir, although HAdV-A31, -B3, -B7, -B11, -B16, -B21, -D8, -D30, and -D37 were less sensitive. Conspicuously, nelfinavir uncovered slow-growing round HAdV-C2 foci, independent of neutralizing antibodies in the medium, indicative of nonlytic cell-to-cell transmission. Our study demonstrates the repurposing potential of nelfinavir with postexposure efficacy against different HAdVs and describes an alternative nonlytic cell-to-cell transmission mode of HAdV.
BibTeX
@inproceedings{georgi2020fda,
  author = {Fanny Georgi and Vardan Andriasyan and Robert Witte and Luca Murer and Silvio Hemmi and Lisa Yu and Melanie Grove and Nicole Meili and Fabien Kuttler and Artur Yakimovich and Gerardo Turcatti and Urs F. Greber},
  title = {{The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus}},
  booktitle = {Antimicrobial},
  year = {2020},
  doi = {10.1128/aac.01002-20},
}
Figure